A Randomized, Open-Label, 6-Period Cross-Over Study to Investigate the Dose Response of Dance 501 (Human Insulin Inhalation Solution and Inhaler) in Subjects With Type 2 Diabetes Mellitus (T2DM)
Latest Information Update: 03 Oct 2021
At a glance
- Drugs Insulin (Primary) ; Insulin lispro
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics; Pharmacokinetics
- Acronyms Samba 04
- Sponsors Aerami Therapeutics; Dance Biopharm
Most Recent Events
- 11 Nov 2019 According to an Aerami Therapeutics media release, findings from two clinical studies (SAMBA-03 and SAMBA-04) will be presented at the 19th Diabetes Technology Meeting taking place on November 14-16, 2019.
- 19 Sep 2019 According to a Dance Biopharm media release, data from this trial were presented at the 55th Annual Meeting of the European Association for the Study of Diabetes on September 19, 2019, in Barcelona, Spain.
- 19 Sep 2019 Results presented in the Dance Biopharm media release.